Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients

Clinical trial NCT02329223 · COMPLETED

Trial details

NCT number: NCT02329223
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Spontaneous Uriticaria

Start date: 2014-12-01
Primary completion: 2015-12-01
Enrollment: 218

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.